NetherlandsTuberculosis profile
Population  2016 17 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.038 (0.037–0.038) 0.22 (0.22–0.23)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.03 (0.02–0.04)
Incidence  (includes HIV+TB) 1 (0.86–1.2) 5.9 (5.1–6.9)
Incidence (HIV+TB only) 0.034 (0.028–0.04) 0.2 (0.17–0.24)
Incidence (MDR/RR-TB)** 0.029 (0.013–0.045) 0.17 (0.08–0.26)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.04 (0.034–0.047) 0.29 (0.25–0.34) 0.33 (0.28–0.38)
Males 0.043 (0.036–0.049) 0.63 (0.54–0.73) 0.68 (0.57–0.78)
Total 0.083 (0.071–0.096) 0.93 (0.79–1.1) 1 (0.86–1.2)
TB case notifications, 2016  
Total cases notified 889
Total new and relapse 877
          - % tested with rapid diagnostics at time of diagnosis 0%
          - % with known HIV status 64%
          - % pulmonary 54%
          - % bacteriologically confirmed among pulmonary 76%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.04 (0.04–0.05)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 19 3%
          - on antiretroviral therapy 13 68%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  15
(6–24)
Estimated % of TB cases with MDR/RR-TB 2% (0.82–4.2) 30% (6.7–65)  
% notified tested for rifampicin resistance 62% 56% 583
MDR/RR-TB cases tested for resistance to second-line drugs   15
Laboratory-confirmed cases MDR/RR-TB: 15, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 15, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 86% 837
Previously treated cases, excluding relapse, registered in 2015 71% 14
HIV-positive TB cases registered in 2015 85% 34
MDR/RR-TB cases started on second-line treatment in 2014 86% 7
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2017  
National TB budget (US$ millions) 33
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-19 Data: www.who.int/tb/data